Posts tagged Biotech Stocks


Valeant Pharmaceuticals Intl Inc (VRX) Gets a Price Target Trim on Uncertainty Circling Legal Liabilities

Deutsche Bank’s Gregg Gilbert is concerned about the unpredictability of VRX’s legal hurdles that lie ahead.

Read more

Here’s Why Vascular Biogenics Ltd (VBLT) Stock Is Slumping Today

Shares of Vascular Biogenics Ltd (NASDAQ:VBLT) slumped on Friday, falling 18% as of 10:30 a.m. EDT, …

Read more

Here’s What’s Behind Heat Biologics Inc (HTBX) Drop Today

After pricing an equity offering that will dilute current investors but help shore up its …

Read more

Teva Pharmaceutical Industries Ltd (ADR) (TEVA) Gets a Price Target Reduction: Can It Hold Its Ground Short-Term?

Mizuho’s Irina Rivkind Koffler says if TEVA can stabilize its business, it could evade a downgrade to high yield.

Read more

Analyst Neil Maruoka Buys on Aurinia Pharmaceuticals Inc (AUPH) for Attractive Worldwide Partnering Potential in Competitive LN Landscape

Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) served its third quarter earnings on Tuesday, but to Canaccord analyst …

Read more

There’s More Than Meets The Eye With Calithera Biosciences

Written by Danny Cohen And Scott Matusow This past weekend at The Society for Immunotherapy …

Read more

Acorda Therapeutics Inc (ACOR) Gets a Price Target Chop Following Fatalities That May Have Been Caused by Tozadenant Drug

J.P. Morgan’s Cory Kasimov is lowering expectations that were never high for ACOR Parkinson’s asset toz.

Read more

This Bull Sees Meaningful Market Potential for Aurinia Pharmaceuticals Inc (AUPH) Drug Voclosporin in Lupus Nephritis

H.C. Wainwright’s Ed Arce spotlights significant prospective value creation for AUPH’s lead asset.

Read more

Teva Pharmaceutical Industries Ltd’s (ADR) (TEVA) Headwinds Need to Be Tackled, But Potential Remains

Cantor’s Louise Chen met with Teva’s team yesterday and still sees reason to be sidelined until generics pricing gets better.

Read more

Here’s Why This Analyst Is Not Counting Immunomedics, Inc. (IMMU) Out of Approval in mTNBC Despite Disappointing SABCS Abstract

Cowen places more importance on ORR strength than reduction in OS for IMMU’s prospects for a green light.

Read more